ArticleHealth science reports2025
A Narrative Review on the Recent Insights Into the Pathogenicity and Potential Role of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in the Emergence of "Disease X".
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Discovery of a 4'-Azido Fleximer Nucleoside Analog With Broad-Spectrum Antiviral Activity Against DENV, EBOV, and Other RNA Viruses.ChemMedChem · 2026Article
- A Narrative Review on the Recent Insights Into the Pathogenicity and Potential Role of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in the Emergence of "Disease X".Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Following the end of the COVID-19 global emergency, concern has shifted to "Disease X," a hypothetical, highly transmissible, and deadly pathogen, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a prime candidate for this. This review explores its epidemiology, mutations, transmission, and potential to become a pandemic-capable pathogen, aiming to support future research and public health preparedness against the disease. Methods: A comprehensive search of major databases was conducted for peer-reviewed English articles (2000-2025) focusing on virology, outbreaks, treatments, and public health using relevant but definite keywords. Studies met strict inclusion criteria and standardized methods to ensure quality, reproducibility, and transparency. Results: Since it was identified in 2012, MERS-CoV has spread across 27 countries, presenting a high case fatality rate (~34.5%) and zoonotic origin. It is primarily linked to dromedary camels, but shows limited human-to-human transmission ( Conclusion: Despite not currently fitting the Disease X archetype, MERS-CoV's high mortality, zoonotic spillover potential, and possibility for increased transmissibility warrant continued surveillance, targeted research, and strengthened public health infrastructure to prevent localized outbreaks from escalating into broader crises.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.